Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study

Annalisa Ruggeri; Giorgia Battipaglia; Myriam Labopin; Gerhard Ehninger; Dietrich Beelen; Johanna Tischer; Arnold Ganser; Rainer Schwerdtfeger; Bertram Glass; Jurgen Finke; Mauricette Michallet; Matthias Stelljes; Pavel Jindra; Renate Arnold; Nicolaus Kröger; Mohamad Mohty; Arnon Nagler

doi:10.1186/s13045-016-0321-y

Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study

Standard

Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. / Ruggeri, Annalisa; Battipaglia, Giorgia; Labopin, Myriam; Ehninger, Gerhard; Beelen, Dietrich; Tischer, Johanna; Ganser, Arnold; Schwerdtfeger, Rainer; Glass, Bertram; Finke, Jurgen; Michallet, Mauricette; Stelljes, Matthias; Jindra, Pavel; Arnold, Renate; Kröger, Nicolaus; Mohty, Mohamad; Nagler, Arnon.

in: J HEMATOL ONCOL, Jahrgang 9, Nr. 1, 17.09.2016, S. 89.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Ruggeri, A, Battipaglia, G, Labopin, M, Ehninger, G, Beelen, D, Tischer, J, Ganser, A, Schwerdtfeger, R, Glass, B, Finke, J, Michallet, M, Stelljes, M, Jindra, P, Arnold, R, Kröger, N, Mohty, M & Nagler, A 2016, 'Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study', J HEMATOL ONCOL, Jg. 9, Nr. 1, S. 89. https://doi.org/10.1186/s13045-016-0321-y

APA

Ruggeri, A., Battipaglia, G., Labopin, M., Ehninger, G., Beelen, D., Tischer, J., Ganser, A., Schwerdtfeger, R., Glass, B., Finke, J., Michallet, M., Stelljes, M., Jindra, P., Arnold, R., Kröger, N., Mohty, M., & Nagler, A. (2016). Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. J HEMATOL ONCOL, 9(1), 89. https://doi.org/10.1186/s13045-016-0321-y

Vancouver

Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J et al. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. J HEMATOL ONCOL. 2016 Sep 17;9(1):89. https://doi.org/10.1186/s13045-016-0321-y

Bibtex

@article{b6fef2404c7d477bb0ae8cd9a9117b75,

title = "Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study",

abstract = "BACKGROUND: Allogeneic stem cell transplantation is the only curative option for patients with acute myeloid leukemia (AML) experiencing relapse. Either matched sibling donor (MSD) or unrelated donor (UD) is indicated.METHODS: We analyzed 1554 adults with AML transplanted from MSD (n = 961) or UD (n = 593, HLA-matched 10/10, n = 481; 9/10, n = 112). Compared to MSD, UD recipients were older (49 vs 52 years, p = 0.001), transplanted more recently (2009 vs 2006, p = 0.001), and with a longer interval to transplant (10 vs 9 months, p = 0.001). Conditioning regimen was more frequently myeloablative for patients transplanted with a MSD (61 vs 46 %, p = 0.001). Median follow-up was 28 (range 3-157) months.RESULTS: Cumulative incidence (CI) of neutrophil engraftment (p = 0.07), grades II-IV acute GVHD (p = 0.11), chronic GVHD (p = 0.9), and non-relapse mortality (NRM, p = 0.24) was not different according to the type of donor. At 2 years, CI of relapse (relapse incidence (RI)) was 57 vs 49 % (p = 0.001). Leukemia-free survival (LFS) at 2 years was 21 vs 26 % (p = 0.001), and overall survival (OS) was 26 vs 33 % (p = 0.004) for MSD vs UD, respectively. Chronic GVHD as time-dependent variable was associated with lower RI (HR 0.78, p = 0.05), higher NRM (HR 1.71, p = 0.001), and higher OS (HR 0.69, p = 0.001). According to HLA match, RI was 57 vs 50 vs 45 %, (p = 0.001) NRM was 23 vs 23 vs 29 % (p = 0.26), and LFS at 2 years was 21 vs 27 vs 25 % (p = 0.003) for MSD, 10/10, and 9/10 UD, respectively. In multivariate analysis adjusted for differences between the two groups, UD was associated with lower RI (HR 0.76, p = 0.001) and higher LFS (HR 0.83, p = 0.001) compared to MSD. Interval between diagnosis and transplant was the other factor associated with better outcomes (RI (HR 0.62, p < 0.001) and LFS (HR 0.67, p < 0.001)).CONCLUSIONS: Transplantation using UD was associated with better LFS and lower RI compared to MSD for high-risk patients with AML transplanted in first relapse.",

keywords = "Journal Article",

author = "Annalisa Ruggeri and Giorgia Battipaglia and Myriam Labopin and Gerhard Ehninger and Dietrich Beelen and Johanna Tischer and Arnold Ganser and Rainer Schwerdtfeger and Bertram Glass and Jurgen Finke and Mauricette Michallet and Matthias Stelljes and Pavel Jindra and Renate Arnold and Nicolaus Kr{\"o}ger and Mohamad Mohty and Arnon Nagler",

year = "2016",

month = sep,

day = "17",

doi = "10.1186/s13045-016-0321-y",

language = "English",

volume = "9",

pages = "89",

journal = "J HEMATOL ONCOL",

issn = "1756-8722",

publisher = "BioMed Central Ltd.",

number = "1",

}

RIS

TY - JOUR

T1 - Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study

AU - Ruggeri, Annalisa

AU - Battipaglia, Giorgia

AU - Labopin, Myriam

AU - Ehninger, Gerhard

AU - Beelen, Dietrich

AU - Tischer, Johanna

AU - Ganser, Arnold

AU - Schwerdtfeger, Rainer

AU - Glass, Bertram

AU - Finke, Jurgen

AU - Michallet, Mauricette

AU - Stelljes, Matthias

AU - Jindra, Pavel

AU - Arnold, Renate

AU - Kröger, Nicolaus

AU - Mohty, Mohamad

AU - Nagler, Arnon

PY - 2016/9/17

Y1 - 2016/9/17

N2 - BACKGROUND: Allogeneic stem cell transplantation is the only curative option for patients with acute myeloid leukemia (AML) experiencing relapse. Either matched sibling donor (MSD) or unrelated donor (UD) is indicated.METHODS: We analyzed 1554 adults with AML transplanted from MSD (n = 961) or UD (n = 593, HLA-matched 10/10, n = 481; 9/10, n = 112). Compared to MSD, UD recipients were older (49 vs 52 years, p = 0.001), transplanted more recently (2009 vs 2006, p = 0.001), and with a longer interval to transplant (10 vs 9 months, p = 0.001). Conditioning regimen was more frequently myeloablative for patients transplanted with a MSD (61 vs 46 %, p = 0.001). Median follow-up was 28 (range 3-157) months.RESULTS: Cumulative incidence (CI) of neutrophil engraftment (p = 0.07), grades II-IV acute GVHD (p = 0.11), chronic GVHD (p = 0.9), and non-relapse mortality (NRM, p = 0.24) was not different according to the type of donor. At 2 years, CI of relapse (relapse incidence (RI)) was 57 vs 49 % (p = 0.001). Leukemia-free survival (LFS) at 2 years was 21 vs 26 % (p = 0.001), and overall survival (OS) was 26 vs 33 % (p = 0.004) for MSD vs UD, respectively. Chronic GVHD as time-dependent variable was associated with lower RI (HR 0.78, p = 0.05), higher NRM (HR 1.71, p = 0.001), and higher OS (HR 0.69, p = 0.001). According to HLA match, RI was 57 vs 50 vs 45 %, (p = 0.001) NRM was 23 vs 23 vs 29 % (p = 0.26), and LFS at 2 years was 21 vs 27 vs 25 % (p = 0.003) for MSD, 10/10, and 9/10 UD, respectively. In multivariate analysis adjusted for differences between the two groups, UD was associated with lower RI (HR 0.76, p = 0.001) and higher LFS (HR 0.83, p = 0.001) compared to MSD. Interval between diagnosis and transplant was the other factor associated with better outcomes (RI (HR 0.62, p < 0.001) and LFS (HR 0.67, p < 0.001)).CONCLUSIONS: Transplantation using UD was associated with better LFS and lower RI compared to MSD for high-risk patients with AML transplanted in first relapse.

AB - BACKGROUND: Allogeneic stem cell transplantation is the only curative option for patients with acute myeloid leukemia (AML) experiencing relapse. Either matched sibling donor (MSD) or unrelated donor (UD) is indicated.METHODS: We analyzed 1554 adults with AML transplanted from MSD (n = 961) or UD (n = 593, HLA-matched 10/10, n = 481; 9/10, n = 112). Compared to MSD, UD recipients were older (49 vs 52 years, p = 0.001), transplanted more recently (2009 vs 2006, p = 0.001), and with a longer interval to transplant (10 vs 9 months, p = 0.001). Conditioning regimen was more frequently myeloablative for patients transplanted with a MSD (61 vs 46 %, p = 0.001). Median follow-up was 28 (range 3-157) months.RESULTS: Cumulative incidence (CI) of neutrophil engraftment (p = 0.07), grades II-IV acute GVHD (p = 0.11), chronic GVHD (p = 0.9), and non-relapse mortality (NRM, p = 0.24) was not different according to the type of donor. At 2 years, CI of relapse (relapse incidence (RI)) was 57 vs 49 % (p = 0.001). Leukemia-free survival (LFS) at 2 years was 21 vs 26 % (p = 0.001), and overall survival (OS) was 26 vs 33 % (p = 0.004) for MSD vs UD, respectively. Chronic GVHD as time-dependent variable was associated with lower RI (HR 0.78, p = 0.05), higher NRM (HR 1.71, p = 0.001), and higher OS (HR 0.69, p = 0.001). According to HLA match, RI was 57 vs 50 vs 45 %, (p = 0.001) NRM was 23 vs 23 vs 29 % (p = 0.26), and LFS at 2 years was 21 vs 27 vs 25 % (p = 0.003) for MSD, 10/10, and 9/10 UD, respectively. In multivariate analysis adjusted for differences between the two groups, UD was associated with lower RI (HR 0.76, p = 0.001) and higher LFS (HR 0.83, p = 0.001) compared to MSD. Interval between diagnosis and transplant was the other factor associated with better outcomes (RI (HR 0.62, p < 0.001) and LFS (HR 0.67, p < 0.001)).CONCLUSIONS: Transplantation using UD was associated with better LFS and lower RI compared to MSD for high-risk patients with AML transplanted in first relapse.

KW - Journal Article

U2 - 10.1186/s13045-016-0321-y

DO - 10.1186/s13045-016-0321-y

M3 - SCORING: Journal article

C2 - 27639553

VL - 9

SP - 89

JO - J HEMATOL ONCOL

JF - J HEMATOL ONCOL

SN - 1756-8722

IS - 1

ER -